Li Yi,Dai Shuyang,Zhan Yong,et al.Correlation analysis of clinical features and outcomes of infantile fibrosarcoma[J].Journal of Clinical Pediatric Surgery,2024,(07):641-647.[doi:10.3760/cma.j.cn101785-202204074-007]
婴儿型纤维肉瘤的临床特征及预后影响因素分析
- Title:
- Correlation analysis of clinical features and outcomes of infantile fibrosarcoma
- Keywords:
- Infantial Fibrosarcoma; Prognosis; Surgical Procedures; Operative; Child
- 摘要:
- 目的 分析婴儿型纤维肉瘤(infantile fibrosarcoma,IFS)的临床特征及治疗效果,并探讨其预后相关因素。方法 本研究为回顾性研究,以2010年1月至2022年1月复旦大学附属儿科医院收治的23例术后病理检查证实为IFS的患儿为研究对象,采用Kaplan-Meier法计算患儿总体生存率和无事件生存率,患儿预后相关因素的单因素分析采用Log-Rank 检验,多因素分析采用Cox回归。结果 23例患儿中,男15例,女8例;发病年龄最小为1天,最大为46个月;发病部位:头颈部4例,躯干13例,四肢6例,首诊时伴肺转移1例;17例肿瘤长径＞5 cm;11例ETS变异转录因子6(ETS variant transcription factor 6,ETV6)-神经营养受体酪氨酸激酶3(neurotrophic receptor tyrosine kinase 3,NTRK3)基因融合检测结果为阳性;16例首诊接受切除手术,7例接受活检手术;术后按照美国横纹肌肉瘤研究组(Intergroup Rhabdomyosarcoma Study,IRS)分期:Ⅰ期9例,Ⅱ期4例,Ⅲ期9例,Ⅳ期1例;5例接受新辅助化疗,其中3例疗效不明显;5例口服拉罗替尼,均疗效良好。截至随访时间,23例中6例因随访时间不满3年删失,IFS 3年总体生存率为(15/17,88.24%),3年无事件生存率为(11/17,64.71%);9例因随访时间不满5年删失,IFS 5年总体生存率为(12/14,85.71%),5年无事件生存率为(9/14,64.29%)。单因素分析结果表明首次手术方式选择切除手术与IFS良好预后相关(χ2=4.938,P=0.026);多因素Cox回归分析显示首次手术方式及术后IRS分期非IFS预后独立影响因素(P＞0.05)。结论 IFS总体预后较好;首诊时接受切除手术对IFS生存有利。新辅助化疗在IFS中的有效性有待探究;拉罗替尼是携带NTRK基因融合、难治性IFS患儿的有效治疗手段。
- Abstract:
- Objective To explore the clinical characteristics and therapeutic outcomes of infantile fibrosarcoma (IFS) and explore the related prognostic factors at a single center. Methods Between January 2010 and January 2022,the relevant clinical data were collected from 23 IFS children.Kaplan-Meier analysis was performed for calculating the values of overall survival (OS) and event-free survival (EFS).Univariate analysis was performed with Log-rank test and multivariate analysis by Cox regression. Results With a male-to-female ratio of 1.86:1,the age was from birth to 46 months.Tumor locations included head & neck (n=4),trunk (n=13) and extremities (n=6).Lung metastasis (n=1) was detected at an initial diagnosis.Seventeen children had tumors with a diameter >5 cm and 11 cases tested positive for ETS variant transcription factor 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) gene fusion.Primary resection (n=16) and biopsy (n=7) were performed.According to the staging scheme of Intergroup Rhabdomyosarcoma Study (IRS),the clinical stages were Ⅰ(n=9),Ⅱ(n=4),Ⅲ(n=9) and Ⅳ(n=1).Among 5 cases on neoadjuvant chemotherapy,efficacy was indefinite (n=3).Five cases taking oral larotrectinib showed a promising efficacy.At the end of follow-up, 6 of 23 cases had been followed for less than 3 years,and 9 less for 5 years.The 3-year OS was (15/17,88.24%) and the 5-year OS was (12/14,85.71%); the 3-year EFS (11/17, 64.71%) and the 5-year EFS rate was (9/14, 64.29%). Univariate analysis revealed that primary resection at an initial diagnosis was associated with a favorable prognosis for IFS (χ2=4.938,P=0.026).Multivariate Cox regression analysis revealed that neither the initial surgical method nor the postoperative IRS stage were independent prognostic factors for IFS (P>0.05). Conclusions The overall prognosis of IFS is favorable.Primary resection at an initial diagnosis is beneficial for the survival of IFS children.The effectiveness of neoadjuvant chemotherapy for IFS requires further investigations.Larotrectinib represents a potential effective therapy for refractory IFS children with NTRK gene fusion.
参考文献/References:
[1] 李仪,董瑞.婴儿型纤维肉瘤的治疗进展[J].中华小儿外科杂志,2020,41(11):1051-1055.DOI:10.3760/cma.j.cn421158-20190730-00464. Li Y,Dong R.Recent therapeutic advances of infantile fibrosarcoma[J].Chin J Pediatr Surg,2020,41(11):1051-1055.DOI:10.3760/cma.j.cn421158-20190730-00464.
[2] Atalay I·B,Togral G.Unusual localization and aggressive progression of large infantile fibrosarcoma[J].Acta Orthop Traumatol Turc,2019,53(6):507-511.DOI:10.1016/j.aott.2019.08.008.
[3] 中华人民共和国国家卫生健康委员会.国家卫生健康委办公厅关于印发儿童血液病、恶性肿瘤相关10个病种诊疗规范(2019年版)的通知.(2019-09-05)[2020-02-16].http://www.nhc.gov.cn/yzygj/s3593/201909/5f1d3329606e4cd2aa6e501603703ee4.shtml. National Health Commission of People’s Republic of China:Notice of General Office of National Health Commission on Promulgating the Diagnosis and Therapeutic Standards for 10 Diseases Related to Pediatric Hematological Diseases and Malignant Tumors (2019 Edition).(2019-09-05) [2020-02-16].http://www.nhc.gov.cn/yzygj/s3593/201909/5f1d3329606e4cd2aa6e501603703ee4.shtml.
[4] 邹继珍,何偲,白云,等.婴儿型纤维肉瘤的临床病理分析[J].中国小儿血液与肿瘤杂志,2017,22(1):18-23.DOI:10.3969/j.issn.1673-5323.2017.01.005. Zou JZ,He C,Bai Y,et al.Clinicopathological analyses of infantile fibrosarcoma[J].J China Pediatr Blood Cancer,2017,22(1):18-23.DOI:10.3969/j.issn.1673-5323.2017.01.005.
[5] 齐广伟,郑佳,马阳阳,等.具有少见组织学特征的婴儿型/先天性纤维肉瘤临床病理学特征[J].中华病理学杂志,2019,48(9):700-704.DOI:10.3760/cma.j.issn.0529?5807.2019.09.007. Qi GW,Zheng J,Ma YY,et al.Clinicopathological analysis of infantile/congenital fibrosarcomas with rare histological features[J].Chin J Pathol,2019,48(9):700-704.DOI:10.3760/cma.j.issn.0529?5807.2019.09.007.
[6] Harel M,Ferrer FA,Shapiro LH,et al.Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma[J].Urol Oncol,2016,34(2):103-115.DOI:10.1016/j.urolonc.2015.09.013.
[7] 汤静燕,潘慈,徐敏,等.儿童横纹肌肉瘤RS-99诊断治疗方案远期临床随访报告[J].中华医学杂志,2009,89(2):121-123.DOI:10.3760/cma.j.issn.0376-2491.2009.02.014. Tang JY,Pan C,Xu M,et al.Long-term clinical follow-up report on the diagnostic and therapeutic protocol RS-99 for pediatric rhabdomysarcoma[J].Natl Med J China,2009,89(2):121-123.DOI:10.3760/cma.j.issn.0376-2491.2009.02.014.
[8] Orbach D,Rey A,Cecchetto G,et al.Infantile fibrosarcoma:management based on the European experience[J].J Clin Oncol,2010,28(2):318-323.DOI:10.1200/JCO.2009.21.9972.
[9] 唐京京,潘慈,高怡瑾,等.术后残留或复发纤维肉瘤患儿26例临床分析[J].中华儿科杂志,2020,58(8):668-673.DOI:10.3760/cma.j.cn112140-20200217-00095. Tang JJ,Pan C,Gao YJ,et al.Clinical analysis of postoperative residual or recurrent fibrosarcoma:a report of 26 cases[J].Chin J Pediatr,2020,58(8):668-673.DOI:10.3760/cma.j.cn112140-20200217-00095.
[10] Kihara S,Nehlsen-Cannarella N,Kirsch WM,et al.A comparative study of apoptosis and cell proliferation in infantile and adult fibrosarcomas[J].Am J Clin Pathol,1996,106(4):493-497.DOI:10.1093/ajcp/106.4.493.
[11] Knezevich SR,McFadden DE,Tao W,et al.A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma[J].Nat Genet,1998,18(2):184-187.DOI:10.1038/ng0298-184.
[12] Albert CM,Davis JL,Federman N,et al.TRK fusion cancers in children:a clinical review and recommendations for screening[J].J Clin Oncol,2019,37(6):513-524.DOI:10.1200/jco.18.00573.
[13] Sparber-Sauer M,Vokuhl C,Seitz G,et al.The impact of local control in the treatment of children with advanced infantile and adult-type fibrosarcoma:experience of the cooperative weichteilsarkom studiengruppe (CWS)[J].J Pediatr Surg,2020,55(9):1740-1747.DOI:10.1016/j.jpedsurg.2019.10.051.
[14] Pappo AS,Devidas M,Jenkins J,et al.Phase II trial of neoadjuvant vincristine,ifosfamide,and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas:a Pediatric Oncology Group Study[J].J Clin Oncol,2005,23(18):4031-4038.DOI:10.1200/JCO.2005.03.209.
[15] Ferrari A.Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas[J].Expert Rev Anticancer Ther,2008,8(6):929-938.DOI:10.1586/14737140.8.6.929.
[16] Church AJ,Calicchio ML,Nardi V,et al.Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy[J].Mod Pathol,2018,31(3):463-473.DOI:10.1038/modpathol.2017.127.
[17] Wong V,Pavlick D,Brennan T,et al.Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to crizotinib[J].J Natl Cancer Inst,2016,108(1):djv307.DOI:10.1093/jnci/djv307.
[18] Laetsch TW,DuBois SG,Mascarenhas L,et al.Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions:phase 1 results from a multicentre,open-label,phase 1/2 study[J].Lancet Oncol,2018,19(5):705-714.DOI:10.1016/S1470-2045(18)30119-0.
[19] Nagasubramanian R,Wei JL,Gordon P,et al.Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101[J].Pediatr Blood Cancer,2016,63(8):1468-1470.DOI:10.1002/pbc.26026.
[20] DuBois SG,Laetsch TW,Federman N,et al.The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas[J].Cancer,2018,124(21):4241-4247.DOI:10.1002/cncr.31701.
相似文献/References:
[1]刘钢高昕刘树立黄柳明王伟邵培侯文英张军李龙.胆道闭锁葛西手术后肝内胆管扩张的治疗与预后分析[J].临床小儿外科杂志,2010,9(03):0.
LIU Gang,GAO Xin,LIU Shu-li,et al.The managements and prognosis of intrahepatic biliary dilatation with biliary atresia after Kasai procedure[J].Journal of Clinical Pediatric Surgery,2010,9(07):0.
[2]沈淳,郑珊,王玮,等.手术年龄对胆道闭锁Kasai手术后预后影响的研究[J].临床小儿外科杂志,2007,6(03):6.
[3]马力,钟微,余家康,等.新生儿肠穿孔危重评分及预后分析[J].临床小儿外科杂志,2007,6(04):10.
[4]金龙 俞钢 陈丹 朱小春 葛午平 林炎坤. 产前诊断脐膨出胎儿80例结局分析[J].临床小儿外科杂志,2011,10(03):199.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):199.
[5]方炜 丁力 张峰 胡英超 陈雨青. 婴幼儿法乐四联症手术治疗近期疗效的影响因素[J].临床小儿外科杂志,2011,10(06):403.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):403.
[6]张金山 李龙 侯文英 刘树立. Ⅲ型胆道闭锁不同亚型与预后关系的探讨[J].临床小儿外科杂志,2012,11(04):244.
[J].Journal of Clinical Pediatric Surgery,2012,11(07):244.
[7]吴德华,田红娟,唐达星,等.AR基因突变雄激素不敏感综合征相关因素在性别分配中的作用分析[J].临床小儿外科杂志,2019,18(05):387.[doi:10.3969/j.issn.1671-6353.2019.05.010]
Wu Dehua,Tian Hongjuan,Tang Daxing,et al.Preliminary study on gender assignments and related predictors of androgen insensitivity syndrome with AR gene mutation[J].Journal of Clinical Pediatric Surgery,2019,18(07):387.[doi:10.3969/j.issn.1671-6353.2019.05.010]
[8]蔡元霞,武志祥,王奕,等.CDC5L表达对神经母细胞瘤临床及预后评估的意义[J].临床小儿外科杂志,2019,18(06):472.[doi:10.3969/j.issn.1671-6353.2019.06.008]
Cai Yuanxia,Wu Zhixiang,Wang Yi,et al.Expression of CDC5L in neuroblastoma and its clinical and prognostic significance[J].Journal of Clinical Pediatric Surgery,2019,18(07):472.[doi:10.3969/j.issn.1671-6353.2019.06.008]
[9]陈籽荣,厉亚坤,万锋.儿童神经肿瘤临床和病理特点[J].临床小儿外科杂志,2019,18(09):723.[doi:10.3969/j.issn.1671-6353.2019.09.003]
Chen Zirong,Li Yakun,Wan Feng.Clinicopathological features of children with neurological tumors[J].Journal of Clinical Pediatric Surgery,2019,18(07):723.[doi:10.3969/j.issn.1671-6353.2019.09.003]
[10]李军亮,许新科,陈程,等.Galen静脉动脉瘤样畸形6例诊治及预后分析[J].临床小儿外科杂志,2019,18(09):744.[doi:10.3969/j.issn.1671-6353.2019.09.007]
Li Junliang,Xu Xinke,Chen Cheng,et al.Diagnosis and treatment of Galen venous aneurysmal malformation: a report of 6 cases[J].Journal of Clinical Pediatric Surgery,2019,18(07):744.[doi:10.3969/j.issn.1671-6353.2019.09.007]
备注/Memo
收稿日期:2022-4-24。
基金项目:唐仲英基金会项目(ZSBK0070)
通讯作者:董瑞,Email:rdong@fudan.edu.cn